Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 High-dose intravenous human immunoglobulin in polymyositis resistant to treatment.

Literature DB >> 1372349

High-dose intravenous human immunoglobulin in polymyositis resistant to treatment.

S Jann¹, S Beretta, M Moggio, L Adobbati, G Pellegrini.

Abstract

Two patients were treated with treatment-resistant polymyositis with intravenous immunoglobulin over four days at a dose of 0.4 g/kg/day. Clinical recovery followed within two months. Serum creatine kinase (CK) activity decreased to normal, and a clear improvement in muscle strength was observed. One patient showed neither clinical relapses nor increase in serum CK activity after 20 months. The other showed a mild increase in serum CK activity after 24 months and was successfully retreated with intravenous immunoglobulin. There were no significant adverse side effects.

Entities: Disease Species

Mesh：

Substances：

Year: 1992 PMID： 1372349 PMCID： PMC488936 DOI： 10.1136/jnnp.55.1.60

Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN： 0022-3050 Impact factor: 10.154

19 in total

1. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study.

Authors: P A van Doorn; A Brand; P F Strengers; J Meulstee; M Vermeulen
Journal: Neurology Date: 1990-02 Impact factor: 9.910

2. Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia.

Authors: D Engelhard; J L Waner; N Kapoor; R A Good
Journal: J Pediatr Date: 1986-01 Impact factor: 4.406

3. High-dose intravenous immunoglobulin in the management of myasthenia gravis.

Authors: E L Arsura; A Bick; N G Brunner; T Namba; D Grob
Journal: Arch Intern Med Date: 1986-07

4. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy.

Authors: J N Whitaker; W K Engel
Journal: N Engl J Med Date: 1972-02-17 Impact factor: 91.245

5. Cyclosporine in the treatment of intractable polymyositis.

Authors: H S Goei The; P Jacobs; H Houben
Journal: Arthritis Rheum Date: 1985-12

6. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis.

Authors: A L Rose; J N Walton
Journal: Brain Date: 1966-12 Impact factor: 13.501

Review 7. Intravenous therapy with gamma globulin.

Authors: J M Dwyer
Journal: Adv Intern Med Date: 1987

8. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy.

Authors: J M Faed; B Day; M Pollock; P K Taylor; H Nukada; G D Hammond-Tooke
Journal: Neurology Date: 1989-03 Impact factor: 9.910

9. Polymyositis/dermatomyositis: clinical features and outcome in 22 patients.

Authors: M Baron; P Small
Journal: J Rheumatol Date: 1985-04 Impact factor: 4.666

10. Polymyositis--treatment and prognosis. A study of 107 patients.

Authors: K G Henriksson; P Sandstedt
Journal: Acta Neurol Scand Date: 1982-04 Impact factor: 3.209

8 in total

1. New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins.

Authors: Martin Stangel
Journal: Ther Adv Neurol Disord Date: 2008-09 Impact factor: 6.570

Review 2. Progressive multifocal leukoencephalopathy during cyclosporine treatment. A case report.

Authors: S Gentile; I Sacerdote; D Roccatello; M T Giordana
Journal: Ital J Neurol Sci Date: 1996-10

3. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.

Authors: Marinos C Dalakas
Journal: Clin Rev Allergy Immunol Date: 2005-12 Impact factor: 8.667